Log In
Print
BCIQ
Print
Print this Print this
 

Netupitant

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionNeurokinin 1 (NK1) Substance P receptor antagonist
Molecular Target Neurokinin 1 (NK1) Substance P receptor (TACR1)
Mechanism of ActionNeurokinin-1 (NK-1) (Substance P) receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation
Partner Helsinn Healthcare S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today